Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. reported total net revenue of $2.98 million for the quarter ended June 30, 2025 (product revenue $2.94M), up from $2.72M a year earlier, and $5.19 million for the six months ended June 30, 2025 versus $5.07M in 2024. Operating expenses rose to $11.0 million for the quarter, producing an operating loss of $8.01 million and a net loss of $10.56 million (six-month net loss $21.16 million).
On the balance sheet, cash fell to $2.21 million at June 30, 2025 from $8.00M at year-end; total assets were $48.27 million and total liabilities $41.39 million. The Company discloses an accumulated deficit of $367.35 million and states its current cash balances are not sufficient to fund its operating plan through one year, noting substantial doubt about continuing as a going concern. Financing during the six months provided $7.62M (including a $3.25M ATM and $3.45M of convertible notes). Revenue remains concentrated: two specialty pharmacy customers accounted for roughly ~88% of product revenue.
Jaguar Health, Inc. (Nasdaq: JAGX) has filed a Rule 424(b)(3) resale prospectus covering 507,390 shares of common stock that may be issued upon exercise of recently issued private-placement warrants. The registration allows the selling stockholders to freely resell: (i) 492,612 shares underlying common warrants priced at $5.84 per share and (ii) 14,778 shares underlying placement-agent warrants priced at $7.6125 per share. All warrants are immediately exercisable and expire on the earlier of (a) 24 months from the May 22 2025 issuance date, (b) a fundamental transaction, or (c) a liquidation event.
The company will receive no proceeds from secondary sales, but would collect up to roughly $3 million in gross proceeds if all warrants are exercised for cash. At the June 26 2025 closing price of $2.71, the warrants are out of the money, making near-term exercise unlikely and limiting immediate cash inflow. Nevertheless, the filing removes resale restrictions and may create an overhang on the stock once prices approach the exercise levels.
Investors should weigh the potential dilution of approximately 507 k shares against the modest, conditional capital infusion and review the company’s previously disclosed risk factors for additional context.
Jaguar Health has filed a prospectus supplement (No. 5) to amend its At-The-Market (ATM) offering program. The key updates include:
Key Details:
- Maximum offering reduced to $3,378,239 worth of common stock shares
- Current stock price: $2.71 per share (as of June 26, 2025)
- Trading symbol: JAGX on Nasdaq
- Non-affiliate market value: approximately $19.0 million (1,463,644 shares at $12.98)
The company has become subject to Form S-3's General Instruction I.B.6 limitations as of March 31, 2025. They have already sold approximately $2.95 million worth of shares in the prior 12-month period. The ATM program is being conducted through Ladenburg Thalmann & Co. and Lucid Capital Markets as sales agents, with all other terms remaining unchanged from the original agreement.
Form 4 Filing: Insider Trading Activity for Jaguar Health (JAGX) reports significant changes in derivative securities holdings by Director Jonathan B. Siegel through JBS Healthcare Ventures LLC on June 24, 2025.
Key transactions include:
- Disposition of original 6% convertible promissory note (9,000 shares at $5.555 conversion price, maturing 6/30/2025)
- Acquisition of new 6% convertible promissory note (9,462 shares at $5.555 conversion price, maturing 1/30/2026)
- Receipt of warrant to purchase 18,262 common shares at $2.70 exercise price, expiring 12/24/2026
The exchange was part of an issuer exchange offer, with the warrant serving as an inducement. The warrant becomes exercisable upon stockholder approval. All securities are held indirectly through JBS Healthcare Ventures LLC, where Siegel serves as sole member.